Summary & Overview
HCPCS Q9956: Injection of Octafluoropropane Microspheres, per mL
HCPCS Level II code Q9956 designates an injectable contrast product: octafluoropropane microspheres billed per milliliter. As a contrast agent code, Q9956 is relevant to diagnostic imaging workflows and reimbursement processes across outpatient imaging centers and hospital radiology departments. Nationally, clear coding for contrast agents affects billing accuracy, payer coverage determinations, and facility cost reporting for imaging services.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage considerations, and clinical context for use in imaging procedures. The publication outlines benchmarks and common billing practices where available, notes policy updates affecting imaging contrast products, and highlights areas providers should document when reporting contrast agent usage. Technical and clinical implications for scheduling, inventory, and charge capture in imaging settings are summarized to support accurate claims submission and reimbursement tracking.
Data not available in the input: detailed payer-specific coverage rules, associated taxonomies, ICD-10 diagnoses, related codes, and service line mappings.
Billing Code Overview
HCPCS Level II code Q9956 represents injection, octafluoropropane microspheres, per ml. This code denotes a radiologic contrast agent supplied as microspheres of octafluoropropane intended for injection and use in imaging procedures that require intravascular or intralesional contrast enhancement.
-
Service type: Contrast agent administration for diagnostic imaging
-
Typical site of service: Outpatient imaging centers or hospital radiology departments where diagnostic imaging procedures (such as ultrasound or other modality-guided studies that utilize injectable microsphere contrast) are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult undergoing diagnostic or interventional ophthalmic or vascular ultrasound procedures in which contrast enhancement is required. A patient with suspected perfusion defects or focal lesions (for example, a patient with reduced retinal perfusion being evaluated for vascular occlusion or a patient undergoing contrast-enhanced echocardiography for endocardial border delineation) presents to an ambulatory imaging center or hospital radiology / cardiology department. The clinician (commonly an ophthalmologist, cardiologist, or radiologist) obtains informed consent, verifies allergies and contraindications, prepares sterile technique as required, and draws the appropriate volume of octafluoropropane microspheres for intravenous injection. The microsphere suspension is administered per institutional protocol, often as a bolus followed by a saline flush, while the imaging team acquires contrast-enhanced ultrasound images. Monitoring for adverse reactions occurs during and after administration. Typical sites of service are outpatient imaging centers, hospital outpatient departments, emergency departments, and inpatient wards when used for diagnostic ultrasound enhancement.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing separate professional interpretation for the ultrasound study that used the contrast agent |